Peiyu Wang

Find an error

Name:
Organization: Peking University
Department: Department of Social Medicine and Health Education
Title:
Co-reporter:Defu Ma, Hiromichi Sakai, Chihiro Wakabayashi, Jong-Sook Kwon, ... Peiyu Wang
Journal of Epidemiology 2017 Volume 27, Issue 12(Volume 27, Issue 12) pp:
Publication Date(Web):1 December 2017
DOI:10.1016/j.je.2016.12.019
•The prevalences of hypertension, diabetes, and hyperlipidemia were highest in China.•The prevalences of hypertension, diabetes, and hyperlipidemia were lowest in Japan.•Some dietary behaviors improved hypertension, diabetes, and hyperlipidemia.•These dietary behaviors differed by sex, age, and marital status.BackgroundNoncommunicable disease (NCD) has become the leading cause of mortality and disease burden worldwide.MethodsA cross-sectional survey was carried out to investigate the prevalence of NCDs and risk factor control on dietary behaviors and dietary intake in China, Japan, and Korea.ResultsThere were significant differences among the three countries on the prevalence of hypertension (24.5% in China, 17.6% in Korea, and 15.2% in Japan), diabetes (8.9% in China, 5.7% in Korea, and 4.8% in Japan), hyperlipidemia (13.1% in China, 9.2% in Korea, and 6.9% in Japan), and angina pectoris (3.6% in China, 1.7% in Korea, and 1.5% in Japan). The prevalence rate of hypertension, diabetes, hyperlipidemia, and angina pectoris was highest in China and lowest in Japan. However, 82.2%, 48.4%, and 64.4% of Chinese, Koreans, and Japanese presented good dietary behavior, respectively. Multivariable logistic regression analysis found that sex, age, and marital status were predictors of good dietary behavior. In addition, in comparison with subjects without hypertension, diabetes, or hyperlipidemia, subjects with hypertension, diabetes, or hyperlipidemia significantly improved their dietary behaviors and controlled their intake of salt, sugar, and oil.ConclusionsThe prevalence of NCDs and trends in major modifiable risk factor control in China, Korea, and Japan remain troubling. Public efforts to introduce healthy lifestyle changes and systematic NCDs prevention programs are necessary to reduce the epidemic of NCDs in these three Asian countries.
Co-reporter:Defu Ma, Yumei Zhang, Yong Xue, Peiyu Wang, Titi Yang, Xianglong Shao
Journal of Functional Foods 2014 Volume 7() pp:580-589
Publication Date(Web):March 2014
DOI:10.1016/j.jff.2013.12.027
•We produced post-menopausal mammary tumour model in ovariectomised rats using DMBA.•Isoflavone/equol treatment inhibited development of post-menopausal mammary tumours.•Antioxidant activity and changing oestrogen receptor expression maybe the mechanism.Studies have yet to determine whether or not equol can explain the chemopreventive effect of soy. In the present study, a single oral dose of 5 mg 7,12-dimethylbenz(a)anthracene (DMBA) was administered to 120 rats. After ovariectomy, these rats were divided into eight different treatment groups: control group (CG); high isoflavone (HI); middle isoflavone (MI); low isoflavone (Li); high equol (HE); middle equol (ME); low equol (LE); and oestrogen group (EG). At week 24 after DMBA was administered, tumour incidences were 60% (9/15) in CG, 13.3% (2/15) in the MI group, 13.3% (2/15) in the Li group, 6.7% (1/15) in the LE group, and 73.3% (11/15) in EG. Isoflavone/equol groups exhibited significantly lower incidences of tumour and longer mean latent period compared with CG and EG. Thiobarbituric acid reactive substances were significantly decreased in the plasma of the rats in HI and MI groups as well as in equol treatment groups compared with CG. Moreover, RT-PCR and western blotting show that the mRNA and protein expression levels of ERα and ERβ were significantly higher in isoflavone/equol treatment groups than in CG. In conclusion, isoflavone/equol intake can significantly inhibit the development of post-menopausal mammary tumours by antioxidant activities and oestrogenic activities.
Co-reporter:Hong Zhou;Li-Qiang Qin;De-Fu Ma;Yan Wang
Environmental Health and Preventive Medicine 2010 Volume 15( Issue 3) pp:162-168
Publication Date(Web):2010 May
DOI:10.1007/s12199-009-0123-8
Milk contains considerable quantities of estrogens and progesterone and as such may be one of the risk factors for hormone-related cancers. To determine the hormonal effects of commercial and traditional types of milk, we performed uterotrophic tests.Forty-five rats were ovariectomized and divided into three groups of 15 animals each. The animals were kept for 7 days on powdered chow and one of three different liquids: commercial milk (C), traditional milk (T), or water. At autopsy, wet and dry uterine weights were determined. The cell heights of the uterine epithelium and endometrium were determined. The uterine 5-bromo-2-deoxyuridine (BrdU) labeling index of the epithelium and endometrium gland epithelium was also assessed.The weights of wet and dry uterus were 142 ± 13 and 112 ± 10 mg in the C group, 114 ± 30 and 91 ± 24 mg in the T group, and 87 ± 6 and 69 ± 5 mg in the W group. Significant differences in wet and dry uterus weights were found between all pairs of groups. The ratio of the wet uterine weight to body weight was significantly higher in the C and T groups than in the W group. The heights of the uterine epithelium and endometrium were higher and BrdU labeling index was greater in the C group than in the T and W groups.Commercially available milk and traditional milk have uterotrophic effects on young ovariectomized rats. Our findings indicate that these uterotrophic effects in the milk groups were partly due to the estrogen and progesterone in the milk.
Co-reporter:Yuhui Shi, Shuyi Guo, Fubao Bo, Xingguang Zhang, Wangnan Cao, Peiyang Wang
International Journal of Infectious Diseases (January 2013) Volume 17(Issue 1) pp:e59-e64
Publication Date(Web):1 January 2013
DOI:10.1016/j.ijid.2012.09.003
ObjectivesThe aim of this study was to evaluate the impact of HIV and sexually transmitted disease (STD) prevention interventions among female sex workers (FSWs) in the city of Hohhot in northern China.MethodsThree serial cross-sectional surveys were conducted in 2006, 2007, and 2008 among FSWs. A questionnaire was administered to the FSWs, and HIV and syphilis tests were performed for all participants. Intervention activities including condom promotion and provision, increased condom availability and accessibility, and voluntary HIV counseling and testing (VCT) were carried out among FSWs.ResultsThere were 624 participants in the 2006 survey, 444 in the 2007 survey, and 451 in the 2008 survey. The United Nations General Assembly Special Session (UNGASS) indicators for FSWs increased from 13.9% in 2006 to 37.7% in 2008 (p < 0.001). The average rate of consistent condom use with commercial clients in the month preceding the interview increased significantly from 39.8% in 2006 to 59.6% in 2008 (p < 0.001). Not a single HIV-positive case was found among the FSWs over these 3 years, and the prevalence of syphilis decreased remarkably from 9.5% in 2006 to 1.3% in 2008. Logistic regression analysis showed that sauna or hair salon work venues, receiving services from intervention programs, and accepting HIV tests were factors associated with consistent condom use.ConclusionsThe findings suggest that consistent condom use and awareness of HIV/AIDS prevention-related knowledge among FSWs have been improved by the intervention. Further prioritized and combined prevention programs aimed at FSWs are needed in order to prevent the HIV/AIDS epidemic spreading in the general population in China.
Guanosine,2'-deoxy-7,8-dihydro-8-oxo-
3-O-Sophoroside,7-O-alpha-L-rhamnopyranoside-3,4',5,7-Tetrahydroxy-3'-methoxyflavone
D-Glucose,O-6-deoxy-a-L-galactopyranosyl-(1®2)-O-b-D-galactopyranosyl-(1®4)-
Glycitin
D-Glucopyranose,O-6-deoxy-a-L-galactopyranosyl-(1®3)-O-b-D-galactopyranosyl-(1®4)-
2-(3,4-dimethoxyphenyl)-5-hydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
Isorhamnetin-3-O-glucoside
8-HYDROXYGUANOSINE
L-chiro-Inositol,2-O-methyl-
ISORHAMNETIN-3-RUTINOSIDE